PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update On 8thOctober 2014
Summary This Report focuses on "PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update " Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing a direct-acting antiviral (DAA), such as Gileads Sovaldi (sofosbuvir) or Janssens Olysio (simeprevir), along with pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and/or ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infections. Sovaldi and Olysio have largely replaced first-generation NS3/4A protease inhibitors, such as Vertexs Incivek (telaprevir) and Mercks Victrelis (boceprevir) due to their increased tolerability, efficacy, and shorter treatment duration. The entrance of next-generation , all-oral HCV therapies is expected to fundamentally alter the HCV treatment algorithm.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-pharmapoint-hepatitis-c-virus-global-drug-forecast-and-marketanalysis-to-2022-event-driven-update-127507
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Highlights Key Questions Answered - How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm? - What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade? - Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period? - Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake? - How will pricing influence the use of next-generation DAAs? - Which HCV regimen(s) in development are physicians most excited about?
Key Findings - Patient awareness is anticipated to increase in response to government education and screening initiatives. - Interferon use is predicted to drastically decrease over the next 10 years. - The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm. - The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect). - Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.
Scope - Overview of hepatitis C virus (HCV), including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines. - Annualized HCV therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2012 and forecast for 10 years to 2022. - Key topics covered include strategic competitor assessment, market characterization, unmet Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
needs, clinical trial mapping and implications for the HCV market. - Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations. - Analysis of the current and future market competition in the global HCV therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges. - Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global HCV therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCV market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global HCV therapeutics market from 2012-2022. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Other industries we cover: • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
•
SWOT Analysis
Table of Content 2 Introduction 22 2.1 Catalyst 22 2.2 Related Reports 22 2.3 Upcoming Related Reports 23 3 Disease Overview 24 3.1 Etiology and Pathophysiology 24 3.1.1 Etiology 24 3.1.2 Pathophysiology 28 3.1.3 Prognosis 29 3.2 Symptoms 29 4 Epidemiology 31 4.1 Risk Factors and Comorbidities 31 4.1.1 The risk of contracting HCV is almost 50 times higher among injection drug users 32 4.1.2 There is a 10.9-fold increased risk of developing HCV infection through a blood transfusion 33 4.1.3 No current preventative therapy to reduce perinatal HCV transmission 33 4.1.4 Metabolic syndrome is a common comorbidity in HCV-infected individuals 34 4.1.5 Chronic alcoholism greatly magnifies the risk of HCC 35 4.1.6 HBV and HCV share similar modes of transmission, resulting in co-infection 35 4.1.7 HCV/HIV co-infection complicates treatment options and accelerates liver damage 35 4.2 Global Trends 36 4.2.1 US 37 4.2.2 5EU 38 4.2.3 Japan 41 4.2.4 Brazil 41 4.2.5 China 42 4.3 Forecast Methodology 43 4.3.1 Sources Used 43 4.3.2 Forecast Assumptions and Methods 47 4.3.3 Forecast Assumptions and Methods (HCV Genotypes) 51 4.3.4 Sources Not Used 55 4.4 Epidemiology Forecast for HCV (2012-2022) 55 4.4.1 Total Prevalent Cases of HCV 55 4.4.2 Age-Specific Prevalent Cases of HCV 58 4.4.3 Sex-Specific Prevalent Cases of HCV 61 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
4.4.4 Age-Standardized Prevalence of HCV 64 4.4.5 HCV Genotype Class Distributions 66 4.5 Discussion 67 4.5.1 Conclusion on Epidemiology Trends 67 4.5.2 Limitations of the Analysis 68 4.5.3 Strengths of the Analysis 69 5 Disease Management 70 5.1 Diagnosis and Referral Overview 70 5.2 Treatment Overview 71 5.3 US 74 5.3.1 Diagnosis 74 5.3.2 Clinical Practice 76 5.4 France 79 5.4.1 Diagnosis 79 5.4.2 Clinical Practice 80 5.5 Germany 81 5.5.1 Diagnosis 81 5.5.2 Clinical Practice 82 5.6 Italy 83 5.6.1 Diagnosis 83 5.6.2 Clinical Practice 83 5.7 Spain 84 5.7.1 Diagnosis 84 5.7.2 Clinical Practice 84 5.8 UK 86 5.8.1 Diagnosis 86 5.8.2 Clinical Practice 87 5.9 Japan 88 5.9.1 Diagnosis 88 5.9.2 Clinical Practice 88 5.10 Brazil 89 5.10.1 Diagnosis 89 5.10.2 Clinical Practice 90 5.11 China 90 5.11.1 Diagnosis 90 5.11.2 Clinical Practice 91 6 Competitive Assessment 92 6.1 Overview 92 6.2 Strategic Competitor Assessment 92 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
6.3 Product Profiles - Major Brands 94 6.3.1 Sovaldi and Sovaldi/Ledipasvir 94 6.3.2 Olysio 106 6.3.3 Incivek 114 6.3.4 Victrelis 121 6.3.5 Pegasys 127 6.3.6 PegIntron 133 6.3.7 Copegus, Rebetol, and Generic Ribavirin 139 6.3.8 Therapeutic Class: Interferon 144 7 Opportunity and Unmet Need 145 7.1 Overview 145 7.2 Unmet Needs 146 7.2.1 Unmet Need: Enhanced Efficacy in Difficult-to-Treat Patient Populations 146 7.2.2 Unmet Need: Improved Understanding of Drug-Drug Interactions 147 7.2.3 Unmet Need: Increased Disease Awareness and Diagnosis of HCV 148 7.2.4 Unmet Need: Reduced Cost of All-Oral Regimens 149 7.2.5 Unmet Need: Improved Treatment Tolerability 149 7.2.6 Unmet Need: Simplified Treatment Algorithm 150 7.2.7 Unmet Need: Shorter Treatment Duration 151 7.3 Unmet Needs Gap Analysis 152 7.4 Opportunities 153 7.4.1 Opportunity: Develop a Pan-Genotypic, All-Oral HCV Regimen 153 7.4.2 Opportunity: Target Difficult-to-Treat Patient Populations 153 7.4.3 Opportunity: Eliminate Ribavirin from All-Oral Regimens 154 7.4.4 Opportunity: Involvement of the Immune System 155 8 Pipeline Assessment 156 8.1 Overview 156 8.2 Clinical Trial Mapping 157 8.2.1 Clinical Trials by Country 157 8.3 Clinical Trials by Phase and Trial Status 158 8.4 Promising Direct-Acting Antivirals (DAAs) in Clinical Development 160 8.4.1 ABT-450/Ombitasvir + Dasabuvir 162 8.4.2 Faldaprevir 172 8.4.3 Daclatasvir, Daclatasvir + Asunaprevir, and Daclatasvir/Asunaprevir/BMS-791325 181 8.4.4 MK-5172/MK-8742 194 8.4.5 Vaniprevir 202 8.5 Other Drug Classes in Clinical Development 208 8.5.1 Interferon Derivatives 208 8.5.2 Host-Targeting Therapies 210 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
9 Current and Future Players 212 9.1 Overview 212 9.2 Trends in Corporate Strategy 214 9.3 Company Profiles 216 9.3.1 Merck 216 9.3.2 Roche 218 9.3.3 Vertex 221 9.3.4 Janssen 224 9.3.5 Gilead 226 9.3.6 AbbVie 231 9.3.7 Bristol-Myers Squibb 233 9.3.8 Boehringer Ingelheim 236 9.4 Additional Companies with Promising Drugs 239 9.4.1 Mitsubishi Tanabe Pharmaceutical Corporation 239 9.4.2 Achillion 240 9.4.3 Scynexis 241 9.4.4 Idenix 242 9.4.5 Presidio 243 9.4.6 Novartis 244 10 Market Outlook 246 10.1 Global Markets 246 10.1.1 Forecast 246 10.1.2 Drivers and Barriers - Global Issues 250 10.2 US 255 10.2.1 Forecast 255 10.2.2 Key Events 261 10.2.3 Drivers and Barriers 262 10.3 France 266 10.3.1 Forecast 266 10.3.2 Key Events 272 10.3.3 Drivers and Barriers 273 10.4 Germany 275 10.4.1 Forecast 275 10.4.2 Key Events 280 10.4.3 Drivers and Barriers 281 10.5 Italy 283 10.5.1 Forecast 283 10.5.2 Key Events 287 10.5.3 Drivers and Barriers 288 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
10.6 Spain 290 10.6.1 Forecast 290 10.6.2 Key Events 294 10.6.3 Drivers and Barriers 295 10.7 UK 297 10.7.1 Forecast 297 10.7.2 Key Events 302 10.7.3 Drivers and Barriers 303 10.8 Japan 305 10.8.1 Forecast 305 10.8.2 Key Events 311 10.8.3 Drivers and Barriers 312 10.9 Brazil 314 10.9.1 Forecast 314 10.9.2 Key Events 318 10.9.3 Drivers and Barriers 318 10.10 China 321 10.10.1 Forecast 321 10.10.2 Key Events 325 10.10.3 Drivers and Barriers 325 11 Appendix 328 11.1 Bibliography 328 11.2 Abbreviations 358 11.3 Methodology 361 11.4 Forecasting Methodology 361 11.4.1 Percent Drug-Treated Patients 361 11.4.2 Patient Warehousing 362 11.4.3 Drugs Included in Each Therapeutic Class 362 11.4.4 Launch and Patent Expiry Dates 363 11.4.5 General Pricing Assumptions 364 11.4.6 Individual Drug Assumptions 365 11.4.7 Generic Erosion 369 11.4.8 Selection of Pipeline Agents 369 11.4.9 Pricing of Pipeline Agents 370 11.5 Physicians and Specialists Included in This Study 374 11.6 Survey of Prescribing Physicians 376 11.7 About the Authors 377 11.7.1 Analysts 377 11.7.2 Epidemiologist 378 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
11.7.3 Therapy Area Director 378 11.7.4 Global Head of Healthcare 379 11.8 About GlobalData 380 11.9 Disclaimer 380
List Of Tables Table 1: Modes of HCV Transmission 28 Table 2: Symptoms of Acute and Chronic HCV Infection 30 Table 3: Risk Factors, Comorbidities, and Complications Associated with HCV Infection 32 Table 4: 9MM, Sources of HCV Prevalence Data Used for the Forecast 44 Table 5: 9MM, Sources of HCV Genotype Data 44 Table 6: Hepatitis C Virus Genotype Description 51 Table 7: 9MM, Prevalent Cases of HCV, Age ≥15 Years, Men and Women, N (Millions), 20122022 56 Table 8: 9MM, Prevalent Cases of HCV, By Age, N (Millions), (Row %), 2012 59 Table 9: 9MM, Prevalent Cases of HCV, by Sex, Ages ≥15 Years, N (Row %), 2012 62 Table 10: 9MM, Prevalent Cases of HCV, by Genotype, Ages ≥15 Years, N (Row %), 2012 66 Table 11: HCV Genotypes Present in the 9MM 71 Table 12: General Standard of Care by HCV Genotype 72 Table 13: Treatment Guidelines for HCV by Country 73 Table 14: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2012 74 Table 15: Leading Treatments for HCV, 2014 94 Table 16: Gilead’s Sovaldi Ongoing Clinical Trials of Interest 96 Table 17: Product Profile - Sovaldi 98 Table 18: Sovaldi’s Most Common Adverse Effects 101 Table 19: Sovaldi SWOT Analysis, 2014 103 Table 20: Global Sales Forecasts ($m) for Sovaldi and Sovaldi/Ledipasvir, 2012-2022 105 Table 21: Janssen’s Olysio Clinical Trials of Interest 107 Table 22: Product Profile - Olysio 109 Table 23: Olysio’s Efficacy - PILLAR Clinical Trial Results 110 Table 24: Olysio’s Safety - Adverse Events Observed in the PILLAR Clinical Trial 111 Table 25: Olysio SWOT Analysis, 2014 113 Table 26: Global Sales Forecasts ($m) for Olysio, 2012-2022 114 Table 27: Product Profile - Incivek 116 Table 28: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 117 Table 29: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 117 Table 30: Common Incivek Adverse Reactions 118 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 31: Incivek SWOT Analysis, 2014 120 Table 32: Global Sales Forecasts ($m) for Incivek, 2012-2022 121 Table 33: Product Profile - Victrelis 122 Table 34: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 123 Table 35: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 124 Table 36: Victrelis SWOT Analysis, 2014 126 Table 37: Global Sales Forecasts ($m) for Victrelis, 2012-2022 127 Table 38: Product Profile - Pegasys 129 Table 39: Antiviral Efficacy of Peginterferon Alfa-2a Compared with Interferon Alfa-2b 130 Table 40: Pegasys SWOT Analysis, 2014 132 Table 41: Global Sales Forecasts ($m) for Pegasys, 2012-2022 133 Table 42: Product Profile - PegIntron 135 Table 43: Antiviral Efficacy of PegIntron Compared With Interferon Alfa-2b 136 Table 44: PegIntron SWOT Analysis, 2014 138 Table 45: Global Sales Forecasts ($m) for PegIntron, 2012-2022 139 Table 46: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 140 Table 47: Ribavirin SWOT Analysis, 2014 142 Table 48: Global Sales Forecasts ($m) for Copegus and Ribavirin, 2012-2022 143 Table 49: Summary of the Minor Therapeutic Classes, 2014 144 Table 50: Overall Unmet Needs - Current Level of Attainment 146 Table 51: Clinical Unmet Needs - Gap Analysis, 2012 152 Table 52: HCV - Clinical Trials by Phase and Status, 2014 159 Table 53: HCV - Late-Stage DAA Pipeline, 2014 160 Table 54: Comparison of Therapeutic Classes in Development for HCV, 2014 162 Table 55: AbbVie’s Combination Therapy Clinical Trials of Interest 164 Table 56: Product Profile - AbbVie Combination Therapy 165 Table 57: AbbVie Combination Therapy - AVIATOR Clinical Trial Results 166 Table 58: AbbVie Combination Therapy - Key Phase III Clinical Trial Results 167 Table 59: AbbVie’s Combination Therapy SWOT Analysis, 2014 171 Table 60: Global Sales Forecasts* ($m) for AbbVie Combination Therapy, 2012-2022 172 Table 61: BI’s Faldaprevir Clinical Trials of Interest 174 Table 62: Product Profile - Faldaprevir 175 Table 63: Faldaprevir SWOT Analysis, 2014 180 Table 64: Global Sales Forecasts ($m) for Faldaprevir, 2012-2022 181 Table 65: BMS’ Combination Therapy Clinical Trials of Interest 183 Table 66: Product Profile - BMS’ Combination Therapy 185 Table 67: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 186 Table 68: Daclatasvir and Asunaprevir Quad Therapy Efficacy 186 Table 69: Daclatasvir Triple Therapy Adverse Events 187 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 70: BMS Combination Therapy SWOT Analysis, 2014 191 Table 71: Global Sales Forecasts ($m) for BMS’ Combination Therapy and Peginterferon Lambda, 2012-2022 193 Table 72: Merck’s Combination Therapy Clinical Trials of Interest 196 Table 73: Product Profile - MK-5172/MK-8742 197 Table 74: MK-5172/MK-8742 SWOT Analysis, 2014 201 Table 75: Global Sales Forecasts ($m) for MK-5172/MK-8742, 2012-2022 202 Table 76: Merck’s Vaniprevir Clinical Trials of Interest 203 Table 77: Product Profile - Vaniprevir 203 Table 78: Vaniprevir SWOT Analysis, 2014 207 Table 79: Global Sales Forecasts ($m) for Vaniprevir, 2012-2022 208 Table 80: Comparison of Peginterferon Lambda with Peginterferon Alfa (EMERGE Trial) 209 Table 81: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 210 Table 82: Key Companies in the HCV Market, 2014 213 Table 83: Merck’s HCV Portfolio Assessment, 2014 217 Table 84: Merck SWOT Analysis, 2014 218 Table 85: Roche’s HCV Portfolio Assessment, 2014 220 Table 86: Roche SWOT Analysis, 2014 221 Table 87: Vertex’s HCV Portfolio Assessment, 2014 223 Table 88: Vertex SWOT Analysis, 2014 223 Table 89: Janssen’s HCV Portfolio Assessment, 2014 225 Table 90: Janssen SWOT Analysis, 2014 226 Table 91: Gilead’s HCV Portfolio Assessment, 2014 229 Table 92: Gilead SWOT Analysis, 2014 230 Table 93: AbbVie’s HCV Portfolio Assessment, 2014 232 Table 94: AbbVie SWOT Analysis, 2014 233 Table 95: BMS’ HCV Portfolio Assessment, 2014 235 Table 96: BMS’ SWOT Analysis, 2014 236 Table 97: BI’s HCV Portfolio Assessment, 2014 238 Table 98: BI SWOT Analysis, 2014 238 Table 99: Mitsubishi Tanabe Pharma’s HCV Portfolio Assessment, 2014 240 Table 100: Achillion’s HCV Portfolio Assessment, 2014 241 Table 101: Scynexis’ HCV Portfolio Assessment, 2014 242 Table 102: Idenix’s HCV Portfolio Assessment, 2014 243 Table 103: Presidio’s HCV Portfolio Assessment, 2014 244 Table 104: Novartis’ HCV Portfolio Assessment, 2014 245 Table 105: Global Sales Forecasts ($m) for HCV, 2012-2022 248 Table 106: HCV Market - Drivers and Barriers, 2012-2022 250 Table 107: Sales Forecasts ($m) for HCV in the US, 2012-2022 259 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 108: Key Events Impacting Sales for HCV in the US, 2012-2022 261 Table 109: US HCV Market - Drivers and Barriers, 2012-2022 262 Table 110: Sales Forecasts ($m) for HCV in France, 2012-2022 270 Table 111: Key Events Impacting Sales for HCV in France, 2012-2022 272 Table 112: French HCV Market - Drivers and Barriers, 2012-2022 273 Table 113: Sales Forecasts ($m) for HCV in Germany, 2012-2022 278 Table 114: Key Events Impacting Sales for HCV in Germany, 2012-2022 280 Table 115: German HCV Market - Drivers and Barriers, 2012-2022 281 Table 116: Sales Forecasts ($m) for HCV in Italy, 2012-2022 285 Table 117: Key Events Impacting Sales for HCV in Italy, 2012-2022 287 Table 118: Italian HCV Market - Drivers and Barriers, 2012-2022 288 Table 119: Sales Forecasts ($m) for HCV in Spain, 2012-2022 292 Table 120: Key Events Impacting Sales for HCV in Spain, 2012-2022 294 Table 121: Spanish HCV Market - Drivers and Barriers, 2012-2022 295 Table 122: Sales Forecasts ($m) for HCV in the UK, 2012-2022 300 Table 123: Key Events Impacting Sales for HCV in the UK, 2012-2022 302 Table 124: UK HCV Market - Drivers and Barriers, 2012-2022 303 Table 125: Sales Forecasts ($m) for HCV in Japan, 2012-2022 309 Table 126: Key Events Impacting Sales for HCV in Japan, 2012-2022 311 Table 127: Japanese HCV Market - Drivers and Barriers, 2012-2022 312 Table 128: Sales Forecasts ($m) for HCV in Brazil, 2012-2022 316 Table 129: Key Events Impacting Sales for HCV in Brazil, 2012-2022 318 Table 130: Brazilian HCV Market - Drivers and Barriers, 2012-2022 318 Table 131: Sales Forecasts ($m) for HCV in China, 2012-2022 323 Table 132: Key Events Impacting Sales for HCV in China, 2012-2022 325 Table 133: Chinese HCV Market - Drivers and Barriers, 2012-2022 325 Table 134: Key Launch Dates 363 Table 135: Key Patent Expiries 364 Table 136: Physicians Surveyed, By Country 376
List Of Figures Figure 1: HCV Genome and Polyprotein Composition 25 Figure 2: HCV Lifecycle Overview 26 Figure 3: 9MM, Prevalent Cases of HCV, Ages ≼15 Years, Men and Women, N (Millions), 20122022 57 Figure 4: 9MM, Prevalent Cases of HCV, by Age, N (Millions), 2012 60 Figure 5: 9MM, Prevalent Cases of HCV, by Sex, N (Millions), 2012 63 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 6: 9MM, Age-Standardized Prevalence of HCV, Ages ≥15 Years, by Sex, %, 2012 65 Figure 7: HCV Therapeutics - Clinical Trials by Country, 2014 158 Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 161 Figure 9: Company Portfolio Gap Analysis in HCV, 2012-2022 214 Figure 10: Global Sales for HCV Therapeutics by Country, 2012-2022 249 Figure 11: Sales for HCV Therapeutics in the US by Drug Class, 2012-2022 260 Figure 12: Sales for HCV Therapeutics in France by Drug Class, 2012-2022 271 Figure 13: Sales for HCV Therapeutics in Germany by Drug Class, 2012-2022 279 Figure 14: Sales for HCV Therapeutics in Italy by Drug Class, 2012-2022 286 Figure 15: Sales for HCV Therapeutics in Spain by Drug Class, 2012-2022 293 Figure 16: Sales for HCV Therapeutics in the UK by Drug Class, 2012-2022 301 Figure 17: Sales for HCV Therapeutics in Japan by Drug Class, 2012-2022 310 Figure 18: Sales for HCV Therapeutics in Brazil by Drug Class, 2012-2022 317 Figure 19: Sales for HCV Therapeutics in China by Drug Class, 2012-2022 324
Report Price: Licence Type
Price
$ 10995
Site Licence
$ 21990
Enterprise Wide Licence
$ 32985
Related Reports: Selecta Biosciences, Inc. – Product Pipeline Review – 2014 Pacific Northwest Biotechnology, LLC – Product Pipeline Review – 2014 Alba Therapeutics Corporation – Product Pipeline Review – 2014 AltraVax Inc. – Product Pipeline Review – 2014 Vitiligo – Pipeline Review, H2 2014 Secondary Hyperparathyroidism – Pipeline Review, H2 2014 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
House Dust Mite Allergy – Pipeline Review, H2 2014 Pulmonary Tuberculosis – Pipeline Review, H2 2014 Post Menopausal Osteoporosis – Pipeline Review, H2 2014 Hairy Cell Leukemia – Pipeline Review, H2 2014
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update http://www.jsbmarketresearch.com/healthcare-medical/r-pharmapointhepatitis-c-virus-global-drug-forecast-and-market-analysis-to-2022-eventdriven-update-127507
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/